Posted by Michael Wonder on 05 Nov 2020
PASC to consider methods for the detection of beta amyloid pathology in patients with early stage Alzheimer's disease to determine eligibility for aducanumab
4 November 2020 - The application from Biogen has requested consideration of two alternative methods for the detection of the presence of beta-amyloid (Aß) pathology in patients in Alzheimer's disease.
The proposed assessments of Aß brain pathology are to identify suitable candidates for treatment with aducanumab.
